Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] What happens to patients with inflammatory bowel disease who are intolerant to thiopurines?
H Gensmyr-Singer, P Karling - Inflammatory Intestinal Diseases, 2024 - karger.com
Introduction: The clinical consequences for patients with inflammatory bowel disease (IBD)
who stop treatment owing to side effects have not been fully investigated. Methods: This …
who stop treatment owing to side effects have not been fully investigated. Methods: This …
The continuing value of mesalazine as first-line therapy for patients with moderately active ulcerative colitis
K Paridaens, MJ Freddi, SPL Travis - Frontiers in Gastroenterology, 2024 - frontiersin.org
Mesalazine is an established and recommended first-line treatment for mild-to-moderate
ulcerative colitis (UC). For patients with moderately active UC, the choice to use mesalazine …
ulcerative colitis (UC). For patients with moderately active UC, the choice to use mesalazine …
[PDF][PDF] What Happens to Patients with Inflammatory Bowel Disease Who Are Intolerant to Thiopurines?
HGSP Karling - 2024 - scienceopen.com
Introduction: The clinical consequences for patients with inflammatory bowel disease (IBD)
who stop treatment owing to side effects have not been fully investigated. Methods: This …
who stop treatment owing to side effects have not been fully investigated. Methods: This …
[PDF][PDF] Drug Class Update: Agents for Inflammatory Bowel Diseases (oral, rectal)
D Moretz - 2021 - orpdl.org
Conclusions:• Since the last P & T Committee review, 9 systematic reviews evaluating
conventional oral and rectal therapy for UC1-5 and CD6-9 were published. Five clinical …
conventional oral and rectal therapy for UC1-5 and CD6-9 were published. Five clinical …